PHGE

PHGE

USD

BiomX Inc. COmmon Stock

$0.440-0.020 (-4.348%)

实时价格

Healthcare
生物技术
以色列

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$0.460

最高价

$0.463

最低价

$0.435

成交量

0.13M

公司基本面

市值

11.5M

所属行业

生物技术

国家/地区

Israel

交易统计

平均成交量

0.13M

交易所

ASE

货币

USD

52周价格范围

最低价 $0.43当前价 $0.440最高价 $3.86

相关新闻

GlobeNewswire

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

查看更多
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15

HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX with a Buy and lowers the price target from $21 to $15.

查看更多
HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15
GlobeNewswire

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report

查看更多
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
GlobeNewswire

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

查看更多
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025